Clinical Trials Directory

Trials / Completed

CompletedNCT01272102

Macular Ganglion Cell Analysis (GCA) of the Cirrus HD-OCT in Glaucoma

Status
Completed
Phase
Study type
Observational
Enrollment
119 (actual)
Sponsor
Carl Zeiss Meditec, Inc. · Industry
Sex
All
Age
40 Years
Healthy volunteers
Not accepted

Summary

To determine the area under the Receiver Operator Characteristic Curve (AUC) for the Ganglion Cell Analysis (GCA) average thickness.

Detailed description

To determine the area under the Receiver Operator Characteristic Curve (AUC) for the following GCA parameters: 1. Minimum thickness 2. Supero-temporal thickness 3. Superior thickness 4. Supero-nasal thickness 5. Infero-temporal thickness 6. Inferior thickness 7. Infero-nasal thickness

Conditions

Timeline

Start date
2010-11-01
Primary completion
2011-03-01
Completion
2011-03-01
First posted
2011-01-07
Last updated
2013-06-25

Locations

4 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT01272102. Inclusion in this directory is not an endorsement.

Macular Ganglion Cell Analysis (GCA) of the Cirrus HD-OCT in Glaucoma (NCT01272102) · Clinical Trials Directory